Adial Pharmaceuticals US patent, enhancing genetic diagnostic coverage for tailored treatment of alcohol and drug dependencies, including opioid use disorder. Learn more about AD04's potential in addressing a $40 billion U
Jim Cramer, the host of CNBC's "Mad Money," has issued a warning to investors about the potential impact of weight loss drugs on the food and beverage industry.
Track Eli Lilly's tripeptide success. Weekly updates on Mounjaro and Zepbound prescriptions in the GLP-1 category. Analyst predicts $12.78 billion in fiscal year 2024 tripeptide revenues.
Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer.